Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions

American Journal of Cardiology

Volumn 116, Issue 9, 2015, Pages 1321-1328

  Page, Robert L ^a   Ghushchyan, Vahram ^b   Read, Richard A ^c   Hartsfield, Cynthia L ^d   Koch, Bruce R ^d   Nair, Kavita V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b AMERICAN UNIVERSITY OF ARMENIA   (Armenia)

^c Peakstat Statistical Services   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; NITRIC ACID DERIVATIVE; RANOLAZINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; VASODILATOR AGENT;

ADULT; AGED; AMBULATORY CARE; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR PROCEDURE; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIABETIC PATIENT; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH IMPACT ASSESSMENT; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RETROSPECTIVE STUDY; REVASCULARIZATION; STABLE ANGINA PECTORIS; ANGINA, STABLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; UTILIZATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA, STABLE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; MALE; NITROGLYCERIN; RANOLAZINE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 84944351826     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.08.002     Document Type: Article

References (21)

1. C.E. Phelps, E.K. Buysman, and G. Gomez Rey Costs and clinical outcomes associated with use of ranolazine for treatment of angina Clin Ther 34 2012 1395 1407
2. H. Ling, K.A. Packard, T.L. Burns, and D.E. Hilleman Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris Am J Cardiovasc Drugs 13 2013 407 412
3. D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S. de Ferranti, J.P. Després, H.J. Fullerton, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H. Mackey, D.B. Matchar, D.K. McGuire, E.R. Mohler 3rd, C.S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, J.Z. Willey, D. Woo, R.W. Yeh, M.B. Turner American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2015 update: a report from the American Heart Association Circulation 131 2015 e29 e322
4. S.D. Fihn, J.M. Gardin, J. Abrams, K. Berra, J.C. Blankenship, A.P. Dallas, P.S. Douglas, J.M. Foody, T.C. Gerber, A.L. Hinderliter, S.B. King 3rd, P.D. Kligfield, H.M. Krumholz, R.Y. Kwong, M.J. Lim, J.A. Linderbaum, M.J. Mack, M.A. Munger, R.L. Prager, J.F. Sabik, L.J. Shaw, J.D. Sikkema, C.R. Smith Jr., S.C. Smith Jr., J.A. Spertus, S.V. Williams, and J.L. Anderson 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 60 2012 e44 e164
5. Healthcare Costs and Utilization Project. Chronic condition indicator for ICD-9-cm. Available at: https://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed on July 10, 2015.
6. N.K. Choudhary, W. Shrank, R.L. Levin, J.L. Lee, S.A. Jan, M.A. Brookhart, and D.H. Solomon Measuring concurrent adherence to multiple related medications Am J Manag Care 15 2009 457 464
7. S.V. Arnold, D.A. Morrow, Y. Lei, D.J. Cohen, E.M. Mahoney, E. Braunwald, and P.S. Chan Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial Circ Cardiovasc Qual Outcomes 2 2009 344 353
8. M. Kosiborod, S.V. Arnold, J.A. Spertus, D.K. McGuire, Y. Li, P. Yue, O. Ben-Yehuda, A. Katz, P.G. Jones, A. Olmsted, L. Belardinelli, and B.R. Chaitman Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina) J Am Coll Cardiol 61 2013 2038 2045
9. A.D. Timmis, B.R. Chaitman, and M. Crager Effects of ranolazine on exercise tolerance and hba1c in patients with chronic angina and diabetes Eur Heart J 27 2006 42 48
10. S.V. Arnold, D.K. McGuire, J.A. Spertus, Y. Li, P. Yue, O. Ben-Yehuda, L. Belardinelli, P.G. Jones, A. Olmsted, B.R. Chaitman, and M. Kosiborod Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin a1c Am Heart J 168 2014 457 465
11. S.V. Arnold, M. Kosiborod, Y. Li, P.G. Jones, P. Yue, L. Belardinelli, and J.A. Spertus Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial Circ Cardiovasc Qual Outcomes 7 2014 844 850
12. D.A. Morrow, B.M. Scirica, B.R. Chaitman, D.K. McGuire, S.A. Murphy, E. Karwatowska-Prokopczuk, C.H. McCabe, and E. Braunwald Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Circulation 119 2009 2032 2039
13. J.W. Chisholm, A.B. Goldfine, A.K. Dhalla, E. Braunwald, D.A. Morrow, E. Karwatowska-Prokopczuk, and L. Belardinelli Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome Diabetes Care 33 2015 1163 1168
14. R.H. Eckel, R.R. Henry, P. Yue, A. Dhalla, P. Wong, P. Jochelson, L. Belardinelli, and J.S. Skyler Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes Diabetes Care 38 2015 1189 1196
15. S. Bangalore, G. Steg, P. Deedwania, K. Crowley, K.A. Eagle, S. Goto, E.M. Ohman, C.P. Cannon, S.C. Smith, U. Zeymer, E.B. Hoffman, F.H. Messerli, and D.L. Bhatt β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease JAMA 308 2012 1340 1349
16. S. Bangalore, D.L. Bhatt, G. Steg, M.A. Weber, W.E. Boden, C.W. Hamm, G. Montalescot, A. Hsu, and K.A. Fox β-Blocker and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA trial Circ Cardiovasc Qual Outcomes 7 2014 872 881
17. C. Andersson, D. Shilane, A.S. Go, T.I. Chang, D. Kazi, M.D. Solomon, D.B. Boothroyd, and M.A. Hlatky Beta-blocker therapy and cardiac events among newly diagnosed coronary heart disease J Am Coll Cardiol 64 2014 247 252
18. Package Insert Ranolazine, Extended Release Tablets, Ranexa 2013 Gilead Sciences Foster City, CA.
19. M.B. Rothberg, S.K. Sivalingam, R. Kleppel, M. Schweiger, B. Hu, and K.R. Sepucha Informed decision making for percutaneous coronary intervention for stable coronary disease JAMA Intern Med 175 2015 1199 1206
20. J. Kempf, E. Buysman, and D. Brixner Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting Am Health Drug Benefits 46 2011 353 361
21. Z. Lu, Y.P. Jiang, C.Y. Wu, L.M. Ballou, S. Liu, E.S. Carpenter, M.R. Rosen, I.S. Cohen, and R.Z. Lin Increased persistent sodium current due to decreased PI3K signaling contributes to qt prolongation in the diabetic heart Diabetes 62 2013 4257 4265